L
Leal Therapeutics
Developing novel therapeutics for patients with major disorders of the central nervous system
About Leal Therapeutics
Leal Therapeutics is a biotechnology company focused on developing innovative therapies for central nervous system (CNS) disorders. The company operates in the biopharmaceutical market, targeting conditions such as Alzheimer's, Parkinson's, and other neurodegenerative diseases. Leal Therapeutics serves patients, healthcare providers, and research institutions by advancing its proprietary drug candidates through clinical trials. The business model is based on research and development (R&D) and strategic partnerships, generating revenue through licensing agreements, milestone payments, and eventual product sales. The company leverages the extensive academic and industry experience of its leadership team, including founders with successful track records in biotech startups and acquisitions. Leal Therapeutics aims to address unmet medical needs by translating cutting-edge science into effective treatments.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Aug 2025 | $30M | $225M | OrbiMed · Euclidean Capital · Dementia Discovery Fund · Alexandria Venture Investments | ↗ |
| EARLY VCOther financing | Oct 2024 | $45M | $180M | OrbiMed · Euclidean Capital · PhiFund Ventures · Alexandria Venture Investments | ↗ |
Growth signals
Latest recorded traffic for Leal Therapeutics is 3.1K monthly website visits, up 34.8% over the last three months. Leal Therapeutics's team grew 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Leal Therapeutics in its local ecosystem
The Leal Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
OrbiMed
PhiFund Ventures
Series A5 investors entered at this stage
Newpath Partners- ECEuclidean Capital
Alexandria Venture Investments- CFChugai Venture Fund
Dementia Discovery Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Leal Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Leal Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










